Insulin-like Growth Factor 1

Insulin-like Growth Factor 1 (IGF-1) is a peptide hormone primarily produced in the liver and plays a crucial role in growth and development. Researchers primarily study IGF-1 for its involvement in various physiological processes, including glucose metabolism, muscle hypertrophy, and cardiovascular health. Key findings indicate that IGF-1 signaling is linked to enhanced glucose uptake and aerobic glycolysis in colorectal cancer, as well as promoting skeletal muscle protein synthesis and regeneration. Additionally, studies suggest that IGF-1 may reduce coronary atherosclerosis and contribute to cardiac adaptation under stress conditions. Current research continues to explore the multifaceted roles of IGF-1 in health and disease, highlighting its potential clinical relevance in metabolic and cardiovascular disorders.

Insulin-like Growth Factor 1 (IGF-1), also known as Somatomedin C or Mecasermin, is an endogenous peptide hormone primarily produced in the liver, although it is also synthesized in other tissues. It belongs to the growth factor category and is structurally similar to insulin. IGF-1 plays a crucial role in growth and development, particularly during childhood, and continues to have anabolic effects in adults. Researchers have extensively studied IGF-1 for its involvement in various physiological processes, including glucose metabolism, muscle hypertrophy, and cardiovascular health. It is also a topic of interest in cancer research, particularly in colorectal cancer, due to its role in metabolic pathways. IGF-1 exerts its effects through binding to the IGF-1 receptor (IGF-1R), activating intracellular signaling cascades such as the PI3K/Akt/mTOR and MAPK pathways. These pathways are involved in cell growth, proliferation, and survival. IGF-1 also influences glucose metabolism by modulating glucose transporters and glycolytic enzymes. Pharmacokinetic properties of IGF-1 include a circulating half-life of approximately 12-15 hours when administered exogenously. It is metabolized primarily in the liver and has limited oral bioavailability due to degradation in the gastrointestinal tract. Clinically, IGF-1 is used in the treatment of growth failure in children with severe primary IGF-1 deficiency. It is also being explored for its potential therapeutic benefits in muscle wasting conditions and cardiovascular diseases. However, due to its potential for misuse in sports, IGF-1 is a prohibited substance by the World Anti-Doping Agency.

IGF-1 acts primarily through the IGF-1 receptor (IGF-1R), initiating signaling cascades such as the PI3K/Akt/mTOR and MAPK pathways. These pathways promote cellular growth, proliferation, and survival, and are involved in glucose uptake and metabolism.

Insulin-like Growth Factor 1 (IGF-1) primarily exerts its effects through the IGF-1 receptor (IGF-1R), activating downstream signaling pathways such as the PI3K/Akt/mTOR and Raf/MAPK pathways. This activation promotes anabolic processes including protein synthesis in skeletal muscle and enhances glucose uptake via glucose transporters like GLUT1, while also inhibiting catabolic pathways associated with muscle atrophy through the suppression of FoxO transcription factors and E3 ubiquitin ligases. Although the precise mechanisms linking IGF-1 to metabolic syndrome and cancer-related metabolic alterations, such as the Warburg effect, remain incompletely understood, IGF-1's role in regulating cellular growth, metabolism, and survival is well established.

Current evidence is limited regarding the specific mechanisms by which IGF-1 signaling interacts with metabolic syndrome and contributes to colorectal cancer progression, necessitating further research to elucidate these pathways and their implications for therapeutic strategies. Additionally, the role of IGF-1 in regulating autophagy during skeletal muscle atrophy remains poorly understood, indicating a need for studies that explore the interplay between IGF-1 signaling, autophagic processes, and muscle regeneration in various chronic disease contexts. Further research is also needed to investigate the long-term effects of IGF-1 treatment on cardiovascular health and atherosclerosis in diverse populations, particularly in human clinical trials to validate findings from animal models.